The medical community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant promise in clinical trials for addressing obesity. Unlike some available weight loss approaches, retatrutide appears to offer a greater substantial decrease in body weight and enhance metabolic function, p